1naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
1nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
)
Summary of imaging features of benign and malignant VCFs
Modality Benign VCF Features Malignant VCF Features MRI: morphology Normal posterior element signal,20 retropulsed bone fragments,9,12,14,17 additional benign VCFs18,19 Abnormal posterior element signal,9–19 epidural or paravertebral soft-tissue mass,9,10,12–15,17–19 expanded posterior vertebral contour,9,11,12,14,18,24 metastasis in other vertebrae9,14,18 MRI: signal and enhancement patterns Preserved normal marrow signal,9–12,14,15,17 regular margins,13,17,28 linear horizontal hypointense T1/T2 band,4,9,11,14,18 fluid sign,9,18,19,26 normal enhancement relative to adjacent vertebrae and at 3 mo12,13,15,28 Geographic replacement of normal marrow signal,11,12,14–18,24,28 irregular margins,13,17,28 increased enhancement relative to adjacent vertebrae and at 3 mo12,13,15,28 MRI: diffusion No restricted diffusion18,27,30,32–45 Increased restricted diffusion18,27,30,32–45 MRI: chemical shift Loss of SI on opposed-phase18,51–53 No change or slight loss of SI on opposed-phase,18,51–53 ratio of opposed-phase to in-phase SI > 0.8–1.018,51–53 CT Retropulsed bone,54,55 puzzle sign,10,54,55 sharp fracture lines,10,54,55 intravertebral vacuum phenomenenon55 Bone destruction,10,54,55 epidural or focal paravertebral soft tissue mass54,55 PET SUV 2 SDs below liver SUV57–60 SUV of >3–4.7 or 2 SDs above liver SUV57–60 SPECT Vertebral body and/or facet joint uptake63 Vertebral body with pedicle and/or spinous process uptake,63 marginal uptake in cold lesion63